Cardiology

Lixisenatide doesn't affect cardiovascular risk in T2DM

(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...

Cardiology

Omega-3 fatty acids, xanthophylls don't cut CVD risk

(HealthDay)—Dietary supplementation with ω-3 polyunsaturated fatty acids or macular xanthophylls do not seem to reduce the risk of cardiovascular disease (CVD) in older adults with age-related macular degeneration, according ...

Diabetes

Metformin cuts cardio events in high-risk type 2 diabetes

(HealthDay)—Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.

Cardiology

Renal denervation improves blood pressure and arterial stiffness

Renal denervation improves blood pressure and arterial stiffness in patients with therapy resistant hypertension, according to research presented at ESC Congress 2012 by Mr Klaas Franzen from the University Hospital of Schleswig-Holstein. ...

page 5 from 6